TAKE2 Health, a Hong Kong healthcare startup, in-licensed global rights to IP for an early nasopharyngeal cancer (NPC) test. The terms of the agreement were not disclosed. The IP was originally licensed to Grail, a US-Hong Kong spin-out from Illumina that is developing early tests for cancer. Professor Dennis Lo, of the University of Hong Kong, developed the IP for the NPC test. Dr. Lo was once head of Grail and is now a co-founder of TAKE2. TAKE2 aims to make the most disruptive healthcare inventions widely accessible to the public in China and Asia.
Source: China Biotoday
